Peptide regulation in the United States spans drug approval pathways, pharmacy compounding lists, and research-use-only catalog commerce. This timeline helps procurement teams orient news headlines to the correct regulatory bucket. It is not legal advice.
2023
FDA continued categorizing nominated bulk drug substances for compounding under 503A. Several peptides appeared on Category 2 (not eligible for compounding) discussions in docket materials — signaling tighter pharmacy compounding boundaries distinct from RUO catalog sales.
2024
Public dockets and FDA communications referenced peptides such as BPC-157, TB-500 fragments, CJC-1295, ipamorelin, AOD-9604, thymosin alpha-1, and selank in compounding and enforcement contexts. Research catalog suppliers emphasized RUO labeling and documentation.
April 2026
FDA bulk drug substances page (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) updated to show BPC-157 under "Bulk drug substances nominated but withdrawn" — not in the active Category 2 interim table. Withdrawal of nomination does not equal FDA approval, does not place BPC-157 on the 503A Bulks List (21 CFR 216.23), and does not authorize compounding. Safety-risk language (immunogenicity / limited human safety data) persists in the withdrawn table. April 14, 2026: nominators (Wells Pharmacy Network, LDT Health Solutions) withdrew BPC-157 nominations (regulations.gov FDA-2015-N-3534-0484/0485). FDA is evaluating at its discretion per PCAC materials.
April 16, 2026
FDA published Federal Register notice (https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request) announcing Pharmacy Compounding Advisory Committee (PCAC) meeting July 23–24, 2026 to discuss BPC-157 (free base and acetate salt) for potential 503A Bulks List inclusion; use evaluated: ulcerative colitis. Advisory committee calendar: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
July 23–24, 2026
Pharmacy Compounding Advisory Committee met July 23–24, 2026 to review BPC-157 (free base and acetate). FDA briefing materials (linked from the meeting page) proposed that BPC-157 NOT be included on the 503A Bulks List. FDA presentation noted nominations were withdrawn and FDA is evaluating at its discretion. Advisory committee recommendations are non-binding. We have not located published minutes as of October 2026; secondary legal-firm reports describe committee discussions but are not official rulemaking. FDA has not finalized rulemaking adding BPC-157 to 21 CFR 216.23 (503A Bulks List) as of October 2026.
September 2026
Chemyo permanently closed September 8, 2026 (official storefront notice). Eternal Peptides wound down with customer support ending September 30, 2026 (storefront thank-you notice). Chameleon Peptides closed to new purchases (storefront notice). See /peptide-vendor-closures for primary sources and procurement guidance. RUO catalog positioning ≠ compounding pharmacy; these closures reflect diverse business factors.
October 14, 2026
Interim access policy for 503A compounding with certain peptides sent to Office of Management and Budget / Office of Information and Regulatory Affairs for review (RIN 0910-ZD94; received by OIRA 10/14/2026; review concluded 10/27/2026, "Consistent with Change"; reginfo.gov). This preceded the October 28 Federal Register filing.
October 28, 2026
HHS filed Federal Register notice FR Doc. 2026-22192 (Docket HHS-OASH-2026-0496, RIN 0910-ZD94) announcing availability of a draft "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." See /blog/hhs-peptide-enforcement-discretion-503a-2026 for full analysis.
October 30, 2026
Federal Register published HHS enforcement discretion policy (Volume 91, Number 209, Pages 68526-68527; https://www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm). HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians compounding with six peptides (BPC-157 acetate, TB-500 acetate, epitalon acetate, semax free base, KPV acetate, MOTS-c acetate) under specified conditions (identity, COA from FDA-registered facility, adverse-event reporting, single-API products, permitted routes) while the 503A bulks list is developed through rulemaking. Policy document with Appendix A (list) and Appendix B (identity/route specifications) at https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf. The policy is limited to 503A compounders; Holland & Knight notes the policy does not extend to research-use-only API, compounding that falls outside its conditions, or peptides not listed in Appendix A. Draft enforcement discretion; not FDA approval; not binding; may be revised if safety or quality issues arise. Public comment deadline: November 13, 2026 (2 weeks after publication) via regulations.gov docket HHS-OASH-2026-0496. See /blog/hhs-peptide-enforcement-discretion-503a-2026 for compound-specific identity tables and analysis.
November 3, 2026
United States Pharmacopeia (USP) issued a public statement (https://www.usp.org/news/usp-statement-on-quality-and-safety-considerations-for-unapproved-peptides) expressing concern that the HHS enforcement discretion policy does not include essential safeguards needed to help ensure quality and safety of compounded preparations. USP noted that the six peptides addressed by the policy do not have USP-NF monographs, USP reference standards, or established bulk drug substance names (USAN, INN, IUPAC) that define their identity and substance-specific quality attributes. USP's review conducted in advance of the PCAC meeting in July 2026 found the peptides not sufficiently characterized to support consistent evaluation of their quality. USP stated: "Without the clearly established identity and appropriate substance-specific standards and reference materials, the quality of the bulk drug substance cannot be reliably and consistently established." USP further stated that the referenced USP standards in the policy "cannot, on their own, provide adequate quality assurance for these peptide substances" because they do not establish the substance- and product-specific quality specifications that would come from linking each peptide to a drug monograph and related reference standard. See /blog/usp-statement-hhs-peptide-policy-2026 for analysis of what monographs, reference standards, and established names establish, how that relates to COA validation, and what laboratories should ask suppliers.
Ongoing
Maintain batch COAs, align purchases with institutional policy, and separate compounding-pharmacy rules (503A/503B) from RUO catalog procurement. Use /guides/ruo-documentation-checklist and /guides/how-to-read-peptide-coa for internal QA files. Monitor FDA.gov for Federal Register notices finalizing any bulk drug substance list additions.
Advisory committee recommendations are non-binding. As of October 2026, FDA has not published final rulemaking adding BPC-157 to the 503A Bulks List (21 CFR 216.23). BPC-157 appears on FDA’s "nominated but withdrawn" table — not approved, not authorized for compounding. RUO catalog sales are a separate question from compounding pharmacy rules. Consult qualified regulatory counsel for your specific use case.